567616

Sodium 4-Phenylbutyrate

A novel anti-neoplastic agent and transcriptional regulator.

• Sinônimo(s): Sodium 4-Phenylbutyrate, SPB, PBNa, 4PBA, 4-Phenylbutyrate, Na, BCKD Kinase Inhibitor I, Branched-Chain α-Ketoacid Dehydrogenase Kinase Inhibitor I, BDK Inhibitor I
• Fórmula empírica (Notação de Hill): C₁₀H₁₁NaO₂
• Número CAS: 1716-12-7
• Peso molecular: 186.18
• Número MDL: MFCD00800247
• Código UNSPSC: 41116107
• NACRES: NA.77

Propriedades

• Nível de qualidade: 100
• Ensaio: ≥98% (HPLC)
• Formulário: solid
• fabricante/nome comercial: Calbiochem^®
• condição de armazenamento: OK to freeze; desiccated (hygroscopic)
• cor: white to slightly yellow
• solubilidade: water: 10 mg/mL
• Condições de expedição: ambient
• temperatura de armazenamento: −20°C
• cadeia de caracteres SMILES: [Na+].[O-]C(=O)CCCc1ccccc1
• InChI: 1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1
• chave InChI: VPZRWNZGLKXFOE-UHFFFAOYSA-M

Descrição

Descrição geral

A novel anti-neoplastic agent and transcriptional regulator. Also acts as an inducer of tumor cytostasis and differentiation. Increases fetal hemoglobin production in vitro and in vivo.

An antineoplastic agent that demonstrates potent differentiating capacity in multiple hematopoietic and solid tumor cell lines. Acts as an inducer of tumor cytostasis and differentiation as well as of peroxisomal proliferation. A more effective inhibitor of histone deacetylase and inducer of histone acetylation than its structural analogs including 2- and 3-phenylbutyrate. Acts as a transcriptional regulator and improve the targeting of δF508-CFTR (cystic fibrosis transmembrane regulator) for ubiquitination and degradation by reducing the expression of HSC70 in epithelial cells. Also, reported to increase fetal hemoglobin production in vitro and in vivo.

Ações bioquímicas/fisiológicas

Cell permeable: no

Primary Target
Anti-neoplastic agent

Product does not compete with ATP.

Reversible: no

Advertência

Toxicity: Standard Handling (A)

Reconstituição

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Outras notas

Tso, S.C., et al. 2013. Proc. Natl. Acad. Sci. USA110, 9728.
Ozcan, U., et al. 2006. Science313, 1137.
Carducci, M.A., et al. 2001. Clin. Cancer Res.7, 3047.
Rubenstein, R.C. and Zeitlin, P.L. 2000. Am.J. Physiol. Cell. Physiol.278, C259.
Lea, M.A., et al. 1999. Anticancer Res.19, 1971.
Miller, A.C., et al. 1997. Int. J. Radiat. Biol. 72, 211.
Rubenstein, R.C., et al. 1997. J. Clin. Invest. 100, 2457.
Pineau, T., et al. 1996. Biochem. Pharmacol. 52, 659.
Collins, A.F., et al. 1995. Blood 85, 43.
Lea, M.A., et al. 1995. Anticancer Res.15, 879.
Figg, W.D., et al. 1994. Anticancer Drugs 5, 336.
Liu, L., et al. 1994. J. Invest. Dermatol. 103, 335.

Informações legais

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Informações de segurança

• Código de classe de armazenamento: 11 - Combustible Solids
• Classe de risco de água (WGK): WGK 3
• Ponto de fulgor (°F): Not applicable
• Ponto de fulgor (°C): Not applicable